featured
MITO-7 Focuses on Quality of Life: Weekly Carboplatin and Paclitaxel vs the Every 3-Week Standard
- Written by
-
Sandro
Pignata
MD
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- De Placido S, Scambia G, Di Vagno G, et al. Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study. J Clin Oncol. 2004;22(13):2635-2642.
- Pignata S, Scambia G, Ferrandina G, et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial. J Clin Oncol. 2011;29(27):3628-3635.
- Pignata S, Scambia G, Katsaros D, et al. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial [published online ahead of print February 27, 2014]. Lancet Oncol. doi: 10.1016/S1470-2045(14)70049-X.
- Katsumata N, Yasuda M, Takahashi F, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009;374(9698):1331-1338.
- Mahner S, Burges A. Quality of life as a primary endpoint in ovarian cancer trials. [published online ahead of print February 27, 2014]. Lancet Oncol. doi: 10.1016/S1470-2045(14)70084-1.